These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11707844)

  • 21. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment.
    Pappa VI; Wilkes S; Salam A; Young BD; Lister TA; Rohatiner AZ
    Bone Marrow Transplant; 1998 Sep; 22(6):553-8. PubMed ID: 9758342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
    Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
    Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
    Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
    Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of t (14; 18) chromosomal translocation in paraffin-embedded tissues of follicular lymphoma and its clinical significance].
    Zhang PH; Zhou XY; Shui RH; Zhang TM; Zheng AH; Guo XH; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):600-4. PubMed ID: 18070448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.
    Johnson PW; Price CG; Smith T; Cotter FE; Meerabux J; Rohatiner AZ; Young BD; Lister TA
    J Clin Oncol; 1994 Apr; 12(4):798-805. PubMed ID: 8151322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma.
    Paszkiewicz-Kozik E; Kulik J; Fabisiewicz A; Tysarowski A; Kraszewska E; Siedlecki JA; Walewski J
    Med Oncol; 2009; 26(1):16-21. PubMed ID: 18470485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
    Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma.
    Berinstein NL; Reis MD; Ngan BY; Sawka CA; Jamal HH; Kuzniar B
    J Clin Oncol; 1993 Jul; 11(7):1344-52. PubMed ID: 8315432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
    Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
    Morschhauser F; Recher C; Milpied N; Gressin R; Salles G; Brice P; Vey N; Haioun C; Colombat P; Rossi JF; Deconinck E; Lazreg F; Bergougnoux L; Delsol G; Attal M
    Ann Oncol; 2012 Oct; 23(10):2687-2695. PubMed ID: 22767588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
    Matsuda I; Hirota S
    Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
    Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
    Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21).
    Ha CS; Lee MS; McLaughlin P; Tucker SL; Wilder RB; Cox JD; Cabanillas F
    Cancer J; 2004; 10(1):49-53. PubMed ID: 15000495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.